|
|
|
| RNA therapeutics are moving beyond scientific promise and into an era defined by scalable execution. Explore expert perspectives on the technologies, strategies, and partnerships shaping the future of RNA across vaccines, oncology, cell therapies, gene editing, and personalized medicine. From overcoming delivery challenges to advancing manufacturing, analytics, and commercialization, this collection examines the key decisions driving progress across the RNA landscape. Click to access the full collection of insights. |
|
|
|
|
By Partha Anbil, MIT Sloan Career Development Office | Raising analytical resolution is among the cheapest interventions available. With regulators tightening and capital selective, it is also among the most consequential. | |
|
|
|
By Advancing RNA Live | As a field, we’ve been aligned around CQAs for our mRNA drug substances. However, differences in translation between highly similar mRNAs (i.e., same sequence, same design, different manufacturers) raise the question of whether we’re missing any QAs/CQAs. Advancing RNA Live panelists Elaine Peters and Ilya Shestolapov share their take. | |
|
|
|
By Nigel Horscroft | mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look. | |
|
|
|
A conversation with Hassan H, Fakih Junior Faculty, UMass Chan Medical School | We discuss how selective albumin binding improved tumor delivery in preclinical studies and what these findings could mean for the future of siRNA-based cancer therapies. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
